Postmarketing surveillance for human teratogenicity: A model approach

Teratology

Volumn 64, Issue 5, 2001, Pages 252-261

  Chambers, Christina D ^a,j   Braddock, Stephen R ^b   Briggs A, Gerald G ^c   Einarson, Drienne ^d   Johnson, Yvette R ^e   Miller, Richard K ^f   Polifka, Janine E ^g   Robinson, Luther K ^h   Stepanuk, Kathleen ⁱ   Jones, Kenneth Lyons ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h UNIVERSITY AT BUFFALO   (United States)

ⁱ THOMAS JEFFERSON UNIVERSITY   (United States)

^j UCSD MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONGENITAL MALFORMATION; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; HUMAN; OUTCOMES RESEARCH; PREGNANCY DISORDER; PRENATAL EXPOSURE; PRIORITY JOURNAL; TERATOGENICITY; TERATOLOGY;

ABNORMALITIES; ABNORMALITIES, DRUG-INDUCED; ABORTION, SPONTANEOUS; COHORT STUDIES; DATA COLLECTION; DRUG UTILIZATION; FEMALE; HUMANS; INFANT, NEWBORN; MALE; PREGNANCY; PREGNANCY OUTCOME; PRODUCT SURVEILLANCE, POSTMARKETING; RESEARCH DESIGN; RISK; TERATOGENS;

EID: 0034765541     PISSN: 00403709     EISSN: None     Source Type: Journal    
DOI: 10.1002/tera.1071     Document Type: Article

References (42)

1. Developmental neurotoxicity of anticonvulsants: Human and animal evidence on phenytoin
2. Reporting bias in retrospective ascertainment of drug-induced embryopathy
3. Chronicity, severity, and timing of maternal depressive symptoms: Relationship with child outcomes at age 5
4. Teratogen update. Reproductive risks of lefiunomide (Arava), a pyrimidine synthesis inhibitor: Counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child
5. Anticonvulsant teratogenesis: Inter-rater agreement in assessing minor physical features relaIed to anticonvulsant therapy
6. Birth outcome in women taking fiuoxetine
7. Maternal fever and birth outcome: A prospective study
8. A prospective study of alcohol exposure during pregnancy: Correlation of quantity with frequency of features characteristic of FAS
9. The fetal valproate syndrome
10. A prospective controlled multicentre study of clarithromycin in pregnancy
11. Neural tube defects in relation to use of folic acid antagonists during pregnancy
12. Predictive value of minor anomalies. II. Use in cohort studies to identify teratogens
13. Need for inclusion and exclusion criteria for the structural abnormalities recorded in children born from exposed pregnancies
14. Influence of maternal active and passive smoking during pregnancy on birthweight in newborns
15. Selection bias in Teratology Information Service pregnancy outcome studies
16. Pattern of malformations in the children of women treated with carbamazepine during pregnancy
17. On the ability of birth defects monitoring to detect new teratogens
18. History of organized teratology information services in North America
19. Diskussionsbemerkung zu dem Vortrag von R.A. Pfeiffer und K. Kosenow: Zur frage der exogenen entstehung schwere extremitatenmissbildungen
20. Predictive value of minor anomalies. I. Association with major malformations
21. In utero exposure to valproate and neural tube defects
22. Maternal flu, fever, and the risk of neural tube defects: A population-based case-control study
23. Congenital anomalies in the newborn infant, including minor variations
24. Problems of using data from Teratology Information Services (TIS) to identify putative teratogens
25. Neurobehavioral followup of children prenatally exposed to fluoxetine
26. Thalidomide and congenital abnormalities
27. An evaluative process for assessing human reproductive and developmental toxicity of agents
28. The risk of spina bifida aperta after first trimester exposure to valproate in a prenatal cohort
29. Congenital malformations associated with the administration of oral anticoagulants during pregnancy
30. Valproate and birth defects
31. Safety of first trimester exposure to topical tretinoin.: A prospective cohort study
32. Pregnancy outcome following first trimester exposure to sumatriptan
33. Palpebral fissure length from 29 weeks gestation to 14 years
34. Impact of prenatal diagnosis and elective termination on prevalence and risk estimate of neural tube defects in California, 1989-1991